公开(公告)号：US20180290965A1

公开(公告)日：2018-10-11

申请号：US16013048

申请日：2018-06-20

Applicant: Novartis AG

Inventor： Luis Brito ,  Delai Chen ,  Gabriel Grant Gamber ,  Andrew Geall ,  Kevin Love ,  Thomas Zabawa ,  Frederic Zecri

IPC: C07C229/12 ,  C07D211/44 ,  A61K39/39 ,  C07C271/22 ,  C07D211/06 ,  A61K31/713 ,  A61K31/7105 ,  A61K9/51 ,  A61K9/127 ,  A61K47/18 ,  C07C219/04 ,  C07C271/20 ,  C07D295/15 ,  C07D211/62 ,  C07D211/60 ,  C07D211/46 ,  C07D295/088 ,  C07D211/22 ,  C07D207/16 ,  C07D207/12 ,  C07D265/30 ,  C07D205/04 ,  C07C229/38 ,  C07D211/34

Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L1, n and p are defined herein. The compounds of formula (X) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

公开(公告)号：US11197826B2

公开(公告)日：2021-12-14

申请号：US16065468

申请日：2016-12-21

Applicant: NOVARTIS AG

Inventor： Ugo D'Oro ,  Luis Brito ,  Derek O'Hagan ,  Silvia Vendetti

IPC: A61K9/107 ,  A61K39/39 ,  A61K31/203 ,  A61K9/00 ,  A61K47/06 ,  A61K45/06 ,  A61K47/22 ,  A61K39/00 ,  A61M5/178

Abstract: Retinoic acid, or an analogue thereof, is delivered within an oil-in-water emulsion to provide an improved immunological adjuvant.

公开(公告)号：US11013696B2

公开(公告)日：2021-05-25

申请号：US16537934

申请日：2019-08-12

Applicant: Novartis AG

Inventor： Luis Brito ,  Delai Chen ,  Gabriel Grant Gamber ,  Andrew Geall ,  Kevin Love ,  Thomas Zabawa ,  Frederic Zecri

IPC: C07D319/06 ,  C07C219/06 ,  C07C229/12 ,  C07D207/12 ,  C07D207/16 ,  C07D211/22 ,  C07D211/62 ,  C07C323/52 ,  A61K31/7105 ,  A61K31/713 ,  C07C219/16 ,  C07D233/60 ,  C07D295/088 ,  C12N15/88 ,  A61K9/51 ,  A61K9/127 ,  A61K47/18 ,  A61K38/18 ,  A61K38/22 ,  A61K39/12 ,  C07C235/08 ,  C07D211/06 ,  C07D211/46 ,  C07D233/64 ,  C07D295/13 ,  C12N7/00 ,  C12N15/113 ,  A61K39/00

Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R3, n, p, L1 and L2 are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

公开(公告)号：US10906867B2

公开(公告)日：2021-02-02

申请号：US16013048

申请日：2018-06-20

Applicant: Novartis AG

Inventor： Luis Brito ,  Delai Chen ,  Gabriel Grant Gamber ,  Andrew Geall ,  Kevin Love ,  Thomas Zabawa ,  Frederic Zecri

IPC: C07C229/12 ,  C07C229/38 ,  C07D205/04 ,  C07D265/30 ,  C07D207/12 ,  C07D207/16 ,  C07D211/22 ,  C07D295/088 ,  C07D211/46 ,  C07D211/60 ,  C07D211/62 ,  C07D295/15 ,  C07C271/20 ,  C07C219/04 ,  A61K47/18 ,  A61K9/127 ,  A61K9/51 ,  A61K31/7105 ,  A61K31/713 ,  A61K39/12 ,  A61K39/39 ,  C07C271/22 ,  C07D211/06 ,  C07D211/34 ,  C07D211/44 ,  A61K39/00

Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L1, n and p are defined herein. The compounds of formula (X) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

公开(公告)号：US10426737B2

公开(公告)日：2019-10-01

申请号：US15104723

申请日：2014-12-17

Applicant: Novartis AG

Inventor： Luis Brito ,  Delai Chen ,  Gabriel Grant Gamber ,  Andrew Geall ,  Kevin Love ,  Thomas Zabawa ,  Frederic Zecri

IPC: C07C219/06 ,  C07C219/16 ,  C07C229/12 ,  C07C235/08 ,  C07C323/52 ,  A61K9/51 ,  C07D319/06 ,  C07D233/60 ,  C07D207/12 ,  C07D207/16 ,  C07D211/22 ,  C07D295/088 ,  C07D211/62 ,  A61K47/18 ,  A61K9/127 ,  A61K31/7105 ,  A61K31/713 ,  C12N15/88 ,  A61K38/18 ,  A61K38/22 ,  A61K39/12 ,  C07D211/06 ,  C07D211/46 ,  C07D233/64 ,  C07D295/13 ,  C12N7/00 ,  C12N15/113 ,  A61K39/00

Abstract: This invention provides for a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1-R3, n, p, L1 and L2 are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

公开(公告)号：US11420933B2

公开(公告)日：2022-08-23

申请号：US17104294

申请日：2020-11-25

Applicant: Novartis AG

Inventor： Luis Brito ,  Delai Chen ,  Gabriel Gamber ,  Andrew Geall ,  Kevin Love ,  Thomas Zabawa ,  Frederic Zecri

IPC: C07C229/12 ,  A61K47/18 ,  C07C229/38 ,  C07D205/04 ,  C07D265/30 ,  C07D207/12 ,  C07D207/16 ,  C07D211/22 ,  C07D295/088 ,  C07D211/46 ,  C07D211/60 ,  C07D211/62 ,  C07D295/15 ,  C07C271/20 ,  C07C219/04 ,  A61K9/127 ,  A61K9/51 ,  A61K31/7105 ,  A61K31/713 ,  A61K39/12 ,  A61K39/39 ,  C07C271/22 ,  C07D211/06 ,  C07D211/34 ,  C07D211/44 ,  A61K39/00

Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L1, n and p are defined herein. The compounds of formula (X) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.